EXPORT CITATION

Chapter-019 Cardiodiabetes and Pulmonary Embolism: Is the Outcome Different?

BOOK TITLE: Cardiodiabetes Update: A Textbook of Cardiology

Author
1. Das Mrinal Kanti
2. Sinha Tapan
ISBN
9789352703043
DOI
10.5005/jp/books/14130_20
Edition
1/e
Publishing Year
2018
Pages
6
Author Affiliations
1. BM Birla Heart Research Center, Kolkata, West Bengal, India, BM Birla Heart Research Centre, Kolkata, West Bengal, India, Braj Birla Heart Research Centre, Kolkata, West Bengal, India, BM Birla Heart Research Centre and Kothari Medical Centre, Kolkata, West Bengal, India, BM Birla Heart Research Centre, Kothari Medical Centre, Kolkata, West Bengal, India, BM Birla Heart Research Center and CMRI, Kolkata, West Bengal, India, Cardiological Society of India; BM Birla Heart Research Centre and Calcutta Medical Research Institute, Kolkata, West Bengal, India, CK Birla Hospital, Kolkata, West Bengal, India; Elect National CSI; Scientific Committee, CSICON-2019, CK Birla Hospitals (BMB/CMRI), Kolkata, West Bengal, India, Asian Heart Society Past President of Cardiological, Society of India, Past Governer of ACC – India Chapter
2. Kothari Medical Centre, Kolkata, West Bengal, India, Kothari Medical Center, Kolkata, West Bengal, India
Chapter keywords
Cardiodiabetes, pulmonary embolism, PE, diabetes mellitus, DM, right ventricular dysfunction, RVD, thrombolysis, platelet dysfunction, T2DM

Abstract

Pulmonary embolism (PE) associated with diabetes mellitus (DM) is a sparsely discussed topic, though the combination is potentially dangerous. PE was present in 2,011 patients with DM (0.7%) versus 2,759 patients (0.5%) in the control group. Pulmonary embolism is an underdiagnosed, potentially life-threatening cardiopulmonary disease. The mortality rate associated with PE is 15% in the first 3 months of diagnosis and nearly 25% cases present with sudden death. Pathophysiology of PE in patients with T2DM is for lipids, altered homeostasis for coagulation derangements and platelet dysfunctions, glycemic control, endothelial damages, and right ventricular dysfunction (RVD). Therapeutic considerations are multifactorial following as thrombolysis, anticoagulants for PE, antithrombotic for platelet dysfunction, treatment for RV dysfunction, treatment outcome for T2DM, and treatment by statins, both as lipid-lowering agent and for their vascular endothelial anti-inflammatory properties.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved